Leonid Timashev
Stock Analyst at DA Davidson
(1.88)
# 2,953
Out of 4,784 analysts
71
Total ratings
32.31%
Success rate
-7.16%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology | Reiterates: Outperform | $8 | $1.06 | +654.72% | 6 | Mar 19, 2025 | |
| BRCC BRC Inc. | Maintains: Buy | $3 | $2.12 | +41.51% | 1 | Mar 19, 2025 | |
| INSM Insmed | Reiterates: Outperform | $100 | $77.99 | +28.22% | 2 | Mar 19, 2025 | |
| ALKS Alkermes | Initiates: Sector Perform | $40 | $33.21 | +20.45% | 1 | Mar 13, 2025 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $56 | $23.27 | +140.65% | 10 | Mar 4, 2025 | |
| BHVN Biohaven | Reiterates: Outperform | $61 | $27.65 | +120.61% | 10 | Mar 4, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $143 → $192 | $118.53 | +61.98% | 8 | Feb 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Reiterates: Outperform | $40 | $21.76 | +83.82% | 6 | Jan 24, 2025 | |
| INCY Incyte | Reiterates: Sector Perform | $70 | $60.60 | +15.51% | 1 | Jan 23, 2025 | |
| CMPS COMPASS Pathways | Reiterates: Outperform | $18 | $2.94 | +512.24% | 4 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $43.19 | +89.86% | 2 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $86 | $35.06 | +145.29% | 12 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $4.21 | -4.99% | 8 | Aug 6, 2024 |
Pyxis Oncology
Mar 19, 2025
Reiterates: Outperform
Price Target: $8
Current: $1.06
Upside: +654.72%
BRC Inc.
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $2.12
Upside: +41.51%
Insmed
Mar 19, 2025
Reiterates: Outperform
Price Target: $100
Current: $77.99
Upside: +28.22%
Alkermes
Mar 13, 2025
Initiates: Sector Perform
Price Target: $40
Current: $33.21
Upside: +20.45%
Edgewise Therapeutics
Mar 4, 2025
Reiterates: Outperform
Price Target: $56
Current: $23.27
Upside: +140.65%
Biohaven
Mar 4, 2025
Reiterates: Outperform
Price Target: $61
Current: $27.65
Upside: +120.61%
Axsome Therapeutics
Feb 19, 2025
Maintains: Outperform
Price Target: $143 → $192
Current: $118.53
Upside: +61.98%
NewAmsterdam Pharma Company
Jan 24, 2025
Reiterates: Outperform
Price Target: $40
Current: $21.76
Upside: +83.82%
Incyte
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $60.60
Upside: +15.51%
COMPASS Pathways
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $2.94
Upside: +512.24%
Dec 18, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $43.19
Upside: +89.86%
Dec 9, 2024
Reiterates: Outperform
Price Target: $86
Current: $35.06
Upside: +145.29%
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $4.21
Upside: -4.99%